Horizon Pharma (HZNP) Tops Q1 EPS by 18c, Revenues Beat; Raises FY19 Revenue Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. EXPE
3. ARM
4. FIS
5. BROS
6. QCOM
7. DDOG
8. EW
9. ZG
10. W

Go back to Horizon Pharma (HZNP) Tops Q1 EPS by 18c, Revenues Beat; Raises FY19 Revenue Guidance Above Consensus

Horizon Therapeutics plc Reports Strong First-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance

May 8, 2019 7:04 AM EDT

-- First-Quarter 2019 Net Sales of $280.4 Million Increased 25 Percent;
First-Quarter 2019 GAAP Net Loss of $32.9 Million; Adjusted EBITDA of $88.4 Million --

-- Quarterly Orphan and Rheumatology Segment Net Sales Increased 8 Percent to $185.9 Million --

-- Increasing Full-Year 2019 Net Sales Guidance Range to $1.26 Billion to $1.28 Billion and
Adjusted EBITDA Guidance Range to $450 Million to $465 Million,
Including the Impact of Incremental Investment in Teprotumumab--

-- Announced Phase 3 Teprotumumab Results That Demonstrate a
Dramatic Reduction in Proptosis in Patients with Active... More